Low-Dose Treatment with Erythropoiesis-Stimulating Agents and Cardiovascular Geometry in Chronic Kidney Disease: Is Darbepoetin-α More Effective than Expected?

Publisher： Karger

E-ISSN： 1664-5502|2|1|18-25

ISSN： 1664-3828

Source： Cardiorenal Medicine, Vol.2, Iss.1, 2011-12, pp. : 18-25

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology

By  

American Journal of Nephrology, Vol. 45, Iss. 3, 2017-02 ,pp. : 235-247

Karger

Access to resources Recommend Favorite

Associations among Darbepoetin-α, CD34+ Cells and Cardiovascular Disease Events in Patients on Hemodialysis

By  

Nephron Extra, Vol. 2, Iss. 1, 2012-09 ,pp. : 233-246

Karger

Access to resources Recommend Favorite

Pre-Emptive Replacement of Water Treatment Components Improves Responsiveness to Erythropoiesis-Stimulating Agents in Maintenance Haemodialysis Patients: A Quality Improvement Report

By  

Blood Purification, Vol. 36, Iss. 3-4, 2013-12 ,pp. : 265-273

Karger

Access to resources Recommend Favorite

Conversion of Darbepoetin to Low Doses of CERA Maintains Hemoglobin Levels in Non-Dialysis Chronic Kidney Disease Patients

By  

Blood Purification, Vol. 30, Iss. 3, 2010-10 ,pp. : 186-194

Karger

Access to resources Recommend Favorite

Dosing of Erythropoiesis-Stimulating Agents Can Be Reduced by a New Administration Regimen

By  

Nephron Extra, Vol. 1, Iss. 1, 2011-08 ,pp. : 45-54

Karger

Access to resources Recommend Favorite